Bone metastases of diverse primary origin frequently express the VDR (vitamin D receptor) and CYP24A1
Zitieren Sie bitte immer diese URN: urn:nbn:de:bvb:20-opus-297377
- Active vitamin D (1,25(OH)2D3) is known to exert direct anti-cancer actions on various malignant tissues through binding to the vitamin D receptor (VDR). These effects have been demonstrated in breast, prostate, renal and thyroid cancers, which all have a high propensity to metastasise to bone. In addition, there is evidence that vitamin D catabolism via 24-hydroxylase (CYP24A1) is altered in tumour cells, thus, reducing local active vitamin D levels in cancer cells. The aim of this study was to assess VDR and CYP24A1 expression in variousActive vitamin D (1,25(OH)2D3) is known to exert direct anti-cancer actions on various malignant tissues through binding to the vitamin D receptor (VDR). These effects have been demonstrated in breast, prostate, renal and thyroid cancers, which all have a high propensity to metastasise to bone. In addition, there is evidence that vitamin D catabolism via 24-hydroxylase (CYP24A1) is altered in tumour cells, thus, reducing local active vitamin D levels in cancer cells. The aim of this study was to assess VDR and CYP24A1 expression in various types of bone metastases by using immunohistochemistry. Overall, a high total VDR protein expression was detected in 59% of cases (39/66). There was a non-significant trend of high-grade tumours towards the low nuclear VDR expression (p = 0.07). Notably, patients with further distant metastases had a reduced nuclear VDR expression (p = 0.03). Furthermore, a high CYP24A1 expression was detected in 59% (39/66) of bone metastases. There was a significant positive correlation between nuclear VDR and CYP24A1 expression (p = 0.001). Collectively, the VDR and CYP24A1 were widely expressed in a multitude of bone metastases, pointing to a potential role of vitamin D signalling in cancer progression. This is of high clinical relevance, as vitamin D deficiency is frequent in patients with bone metastases.…
Autor(en): | Jonas Seiler, Regina Ebert, Maximilian Rudert, Marietta Herrmann, Ellen Leich, Manuela Weißenberger, Konstantin Horas |
---|---|
URN: | urn:nbn:de:bvb:20-opus-297377 |
Dokumentart: | Artikel / Aufsatz in einer Zeitschrift |
Institute der Universität: | Medizinische Fakultät / Pathologisches Institut |
Medizinische Fakultät / Lehrstuhl für Orthopädie | |
Medizinische Fakultät / Comprehensive Cancer Center Mainfranken | |
Sprache der Veröffentlichung: | Englisch |
Titel des übergeordneten Werkes / der Zeitschrift (Englisch): | Journal of Clinical Medicine |
ISSN: | 2077-0383 |
Erscheinungsjahr: | 2022 |
Band / Jahrgang: | 11 |
Heft / Ausgabe: | 21 |
Aufsatznummer: | 6537 |
Originalveröffentlichung / Quelle: | Journal of Clinical Medicine (2022) 11:21, 6537. https://doi.org/10.3390/jcm11216537 |
DOI: | https://doi.org/10.3390/jcm11216537 |
Sonstige beteiligte Institutionen: | Lehrstuhl für Regeneration Muskuloskelettaler Gewebe |
Sonstige beteiligte Institutionen: | IZKF Nachwuchsgruppe Geweberegeneration für muskuloskelettale Erkrankungen |
Sonstige beteiligte Institutionen: | Muskuloskelettales Centrum Würzburg (MCW) |
Allgemeine fachliche Zuordnung (DDC-Klassifikation): | 6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit |
Freie Schlagwort(e): | CYP24A1; VDR; bone metastasis; vitamin D; vitamin D receptor |
Datum der Freischaltung: | 13.11.2023 |
Datum der Erstveröffentlichung: | 03.11.2022 |
Lizenz (Deutsch): | CC BY: Creative-Commons-Lizenz: Namensnennung 4.0 International |